Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation [Phase 2]

View source ↗

Summary

Phase 2 study of HSY244 in Atrial Fibrillation was terminated, and results were posted in July 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• HSY244

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atrial Fibrillation | Phase 2 | Status: TERMINATED | Results posted: 2023-07-25